Is 4D Molecular Therapeutics Inc (FDMT) a Leader in the Healthcare Sector?

The 67 rating InvestorsObserver gives to 4D Molecular Therapeutics Inc (FDMT) stock puts it near the top of the Healthcare sector. In addition to scoring higher than 92 percent of stocks in the Healthcare sector, FDMT’s 67 overall rating means the stock scores better than 67 of all stocks.

FDMT has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on FDMT!

See Full FDMT Report

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. *Investors Observer* makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With 4D Molecular Therapeutics Inc Stock Today?

4D Molecular Therapeutics Inc (FDMT) stock is down -8.14% while the S&P 500 has gained 0.04% as of 9:45 AM on Thursday, Mar 28. FDMT is down -$2.92 from the previous closing price of $35.87 on volume of 31,644 shares. Over the past year the S&P 500 is up 30.36% while FDMT has gained 85.11%. FDMT lost -$2.58 per share the over the last 12 months. Click Here to get the full Stock Report for 4D Molecular Therapeutics Inc stock.